EuroBiotech—More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Acacia Pharma filed for an IPO. The British drug developer plans to list its stock on the Euronext exchange in Brussels. Acacia’s choice of Brussels comes a little more than two years after it dropped plans to raise £150 million ($210 million) in London. Statement (PDF)

> Sol-Gen Technologies raised $86.3 million on Nasdaq. The Israeli company will use the money to run phase 3 clinical trials in patients with acne and a form of the skin condition rosacea. Release  

> Adocia is seeking $200 million in damages from Eli Lilly. The arbitration claims relate to “Lilly’s misappropriation and improper use of Adocia’s confidential information and discoveries as well as Lilly’s breaches of several collaboration and confidentiality agreements,” the French biotech said in a statement. Adocia expects to receive a decision on the claims—and an earlier filing against Lilly—by the third quarter of 2018. Statement  

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

> Redx dosed the first patient in a phase 1/2a trial of Porcupine inhibitor RXC004. The trial is an early step in Redx’s attempts to bounce back from the financial difficulties that forced it to offload a BTK inhibitor to Loxo Oncology for $40 million. Release

> A phase 3 trial of Bavarian Nordic’s smallpox vaccine hit both its primary endpoints. The success of the second phase 3 trial positions the Danish drugmaker to file for FDA approval in the back half of the year. Statement

> TC BioPharm (TCB) entered into a collaboration with Nipro. The alliance is built upon TCB’s CAR-T platform. Release